^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PRT062607

i
Other names: P505-15, PRT062607, PRT2607, PRT 062607, PRT-2607, BIIB-057, BIIB057, P 50515
Associations
Trials
Company:
AstraZeneca, Biogen
Drug class:
SYK inhibitor
Associations
Trials
over3years
Spleen Tyrosine Kinase (SYK) Inhibitor PRT062607 Protects Against Ovariectomy-Induced Bone Loss and Breast Cancer-Induced Bone Destruction. (PubMed, Biochem Pharmacol)
Further, we proved that PRT could prevent post-ovariectomy (OVX) loss of bone and breast cancer-induced bone destruction in vivo, which agreed with the in vitro outcomes. In conclusion, our findings suggest the potential value of PRT in managing osteolytic diseases mediated by osteoclasts.
Journal
|
SYK (Spleen tyrosine kinase)
|
PRT062607
5years
Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia (ASH 2019)
We found drug response profiles to be correlated closely for drugs targeting the same signaling-pathway, e.g. the B-cell receptor inhibitors Ibrutinib (BTK) and PRT062607 (Syk) (Pearson correlation coefficient: r=0.78, 95% CI: 0.72 - 0.83)...3) The microenvironmental stimulus and the drug exhibited no major individual effect on CLL cell survival, but together significantly increased CLL cell viability (e.g. Interferon-γ:Ralimetinib, p-value: < 0.0001)...A high signaling activity of IL-4 was associated with shorter time to treatment, indicating that CLL progresses faster with strong microenvironmental support. Conclusion We present a systematic investigation on the tumor microenvironment in CLL, the underlying molecular determinants as well its interference with drug response which will serve as a scientific resource and starting point for further mechanistical investigations.
IO biomarker
|
IL6 (Interleukin 6) • IL2 (Interleukin 2) • SYK (Spleen tyrosine kinase) • CD40LG (CD40 ligand)
|
Imbruvica (ibrutinib) • PRT062607 • ralimetinib (LY 2228820)